Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,607 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK, Fan PD, Qeriqi B, Namakydoust A, Daly B, Ahn L, Kim R, Plodkowski A, Ni A, Chang J, Fanaroff R, Ladanyi M, de Stanchina E, Rudin CM. Paik PK, et al. Among authors: kim r. J Thorac Oncol. 2023 Apr;18(4):516-526. doi: 10.1016/j.jtho.2022.09.225. Epub 2022 Oct 12. J Thorac Oncol. 2023. PMID: 36240971 Free PMC article.
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
Paik PK, Kim RK, Ahn L, Plodkowski AJ, Ni A, Donoghue MTA, Jonsson P, Villalona-Calero M, Ng K, McFarland D, Fiore JJ, Iqbal A, Eng J, Kris MG, Rudin CM. Paik PK, et al. Clin Cancer Res. 2020 Apr 15;26(8):1796-1802. doi: 10.1158/1078-0432.CCR-19-3060. Epub 2020 Jan 9. Clin Cancer Res. 2020. PMID: 31919132 Free PMC article. Clinical Trial.
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, Tobi Y, Heller G, Ahn L, Hayes SA, Young RJ, Arcila ME, Berger M, Chaft JE, Ladanyi M, Riely GJ, Kris MG. Yu HA, et al. Among authors: kim r. JAMA Oncol. 2020 Jul 1;6(7):1048-1054. doi: 10.1001/jamaoncol.2020.1260. JAMA Oncol. 2020. PMID: 32463456 Free PMC article. Clinical Trial.
Very early vs delayed invasive strategy in high-risk NSTEMI patients without hemodynamic instability: Insight from the KAMIR-NIH.
Lee SD, Kim RB, Seo CO, Kim M, Lee HJ, Kim H, Kim HR, Kim K, Kang MG, Park JR, Hwang SJ, Hwang JY, Jeong MH, Hur SH, Cha KS, Koh JS; KAMIR-NIH registry investigators. Lee SD, et al. Among authors: kim rb. PLoS One. 2024 Jun 6;19(6):e0304273. doi: 10.1371/journal.pone.0304273. eCollection 2024. PLoS One. 2024. PMID: 38843207 Free article.
Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease.
Tai CC, Medwid S, Mclntosh K, Chande N, Kim RB, Gregor J. Tai CC, et al. Among authors: kim rb. J Can Assoc Gastroenterol. 2024 Feb 10;7(3):238-245. doi: 10.1093/jcag/gwae005. eCollection 2024 Jun. J Can Assoc Gastroenterol. 2024. PMID: 38841142 Free PMC article.
Increased endothelial sclerostin caused by elevated DSCAM mediates multiple trisomy 21 phenotypes.
McKean DM, Zhang Q, Narayan P, Morton SU, Strohmenger V, Tang VT, McAllister S, Sharma A, Quiat D, Reichart D, DeLaughter DM, Wakimoto H, Gorham JM, Brown K, McDonough B, Willcox JA, Jang MY, DePalma SR, Ward T; Pediatric Cardiac Genomics Consortium Investigators; Kim R, Cleveland JD, Seidman JG, Seidman CE. McKean DM, et al. Among authors: kim r. J Clin Invest. 2024 Jun 3;134(11):e167811. doi: 10.1172/JCI167811. J Clin Invest. 2024. PMID: 38828726 Free PMC article.
4,607 results